Chromocell Therapeutics (Chromocell Therapeutics) Accounts Payable & Accrued Expense : $2.41 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Chromocell Therapeutics Accounts Payable & Accrued Expense?

Chromocell Therapeutics's quarterly accounts payable & accrued expense increased from Sep. 2023 ($4.17 Mil) to Dec. 2023 ($4.63 Mil) but then declined from Dec. 2023 ($4.63 Mil) to Mar. 2024 ($2.41 Mil).

Chromocell Therapeutics's annual accounts payable & accrued expense increased from Dec. 2021 ($2.58 Mil) to Dec. 2022 ($3.00 Mil) and increased from Dec. 2022 ($3.00 Mil) to Dec. 2023 ($4.63 Mil).

Chromocell Therapeutics Accounts Payable & Accrued Expense Historical Data

The historical data trend for Chromocell Therapeutics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chromocell Therapeutics Accounts Payable & Accrued Expense Chart

Chromocell Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

3.41

2.58

3.00

4.63

Chromocell Therapeutics Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial							3.37	3.55	4.17	4.63	2.41

Chromocell Therapeutics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Chromocell Therapeutics (Chromocell Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chromocell Therapeutics Corp (AMEX:CHRO) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Chromocell Therapeutics Corp is a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Its clinical focus is to selectively target the sodium ion-channel known as "NaV1.7", as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology.